What Do the Prasinezumab and Coramitug Programs Mean for Prothena Corporation plc (NASDAQ:PRTA) in 2026?

Sonal Goyal

06 November 2026 11:01 PM AEDT

What Do the Prasinezumab and Coramitug Programs Mean for Prothena Corporation plc (NASDAQ:PRTA) in 2026?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Prasinezumab and coramitug are both in Phase 3 clinical trials.
Primary completions for the two Phase 3 programs are expected in 2029.
Novo presented a post hoc analysis of coramitug's Phase 2 trial at the HFSA meeting.
A Phase 2 readout for moponetug in early Alzheimer's disease is expected in the first half of 2027.

Prothena Corporation plc (NASDAQ:PRTA) described itself as a late-stage clinical biotechnology company focused on protein dysregulation. The company reported third quarter and first nine months 2026 results and provided updates on its pipeline. Chief Executive Gene Kinney highlighted the progress of two programs developed by Prothena and advanced by partners: prasinezumab and coramitug, both now in Phase 3 clinical trials.

Prasinezumab and Coramitug Programs

Roche highlighted prasinezumab, a Parkinson's disease candidate, at its Pharma Day during the quarter. Novo Nordisk highlighted coramitug, which targets ATTR amyloidosis with cardiomyopathy, at its Capital Markets Day. The release describes both as Prothena-originated programs that address significant unmet needs, underscoring the value of the underlying scientific platform to partners.

The Phase 3 trials, named PARAISO for prasinezumab and CLEOPATTRA for coramitug, have primary completions expected in 2029. Those timelines mean the programs are likely to remain in clinical development for several years, and their results will determine the eventual commercial value of the partnerships.

Clinical Data and Scientific Findings

Novo presented a post hoc analysis of the coramitug Phase 2 trial at the HFSA Annual Scientific Meeting. The analysis showed that the inflammatory biomarker hsCRP decreased from baseline in patients treated with coramitug, while it increased in those receiving placebo. The finding complements earlier reported data, according to the release.

Post hoc analyses are exploratory by nature, and they generate hypotheses rather than confirm efficacy. The hsCRP finding is therefore best read as supportive background for the Phase 3 program, which will provide the formal evidence needed to assess clinical benefit.

Partner Programs and Upcoming Milestones

Bristol Myers Squibb continues to run the Phase 2 TargetTau-1 trial evaluating moponetug in patients with early Alzheimer's disease. For Prothena, the progress of partnered programs is a key element of its value, since the company's Revenue and milestones depend on partner decisions.

The company also referred to its CYTOPE technology and said it expects to communicate potential progress over the next 12 to 24 months.

Final Takeaways

Prothena's third quarter update centers on two Phase 3 programs with primary completions expected in 2029, supporting scientific findings and partner milestones along the way. The company is dependent on partner development progress for much of its near-term visibility. Future updates on the Phase 3 trials, the moponetug readout and CYTOPE progress will indicate how the pipeline develops.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.